Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease
- PMID: 20553970
- DOI: 10.1016/j.arr.2010.05.003
Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease
Abstract
Perturbed neuronal calcium homeostasis is a prominent feature in Alzheimer's disease (AD). Mitochondria accumulate calcium ions (Ca(2+)) for cellular bioenergetic metabolism and suppression of mitochondrial motility within the cell. Excessive Ca(2+) uptake into mitochondria often leads to mitochondrial membrane permeabilization and induction of apoptosis. Ca(2+) is an interesting second messenger which can initiate both cellular life and death pathways in mitochondria. This review critically discusses the potential of manipulating mitochondrial Ca(2+) concentrations as a novel therapeutic opportunity for treating AD. This review also highlights the neuroprotective role of a number of currently available agents that modulate different mitochondrial Ca(2+) transport pathways. It is reasoned that these mitochondrial Ca(2+) modulators are most effective in combination with agents that increase the Ca(2+) buffering capacity of mitochondria. Modulation of mitochondrial Ca(2+) handling is a potential pharmacological target for future development of AD treatments.
Copyright © 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Novel neuroprotective compound SCH-20148 rescues thymocytes and SH-SY5Y cells from thapsigargin-induced mitochondrial membrane potential reduction and cell death.Eur J Pharmacol. 2007 Jun 1;563(1-3):40-8. doi: 10.1016/j.ejphar.2007.01.060. Epub 2007 Feb 8. Eur J Pharmacol. 2007. PMID: 17343843
-
Aluminum modulates effects of beta amyloid(1-42) on neuronal calcium homeostasis and mitochondria functioning and is altered in a triple transgenic mouse model of Alzheimer's disease.Rejuvenation Res. 2008 Oct;11(5):861-71. doi: 10.1089/rej.2008.0761. Rejuvenation Res. 2008. PMID: 18788899
-
In vitro galantamine-memantine co-application: mechanism of beneficial action.Neuropharmacology. 2006 Dec;51(7-8):1181-91. doi: 10.1016/j.neuropharm.2006.08.007. Epub 2006 Sep 29. Neuropharmacology. 2006. PMID: 17011596
-
Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death?J Neurosci Res. 2005 Jan 1-15;79(1-2):231-9. doi: 10.1002/jnr.20292. J Neurosci Res. 2005. PMID: 15573402 Review.
-
Mitochondrial mechanisms of estrogen neuroprotection.Brain Res Rev. 2008 Mar;57(2):421-30. doi: 10.1016/j.brainresrev.2007.04.007. Epub 2007 Apr 27. Brain Res Rev. 2008. PMID: 17512984 Review.
Cited by
-
Dual phases of respiration chain defect-augmented mROS-mediated mCa 2+ stress during oxidative insult in normal and ρ 0 RBA1 astrocytes.Oxid Med Cell Longev. 2013;2013:159567. doi: 10.1155/2013/159567. Epub 2013 Mar 10. Oxid Med Cell Longev. 2013. PMID: 23533684 Free PMC article.
-
Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside.Mol Neurobiol. 2022 Jul;59(7):4384-4404. doi: 10.1007/s12035-022-02859-7. Epub 2022 May 12. Mol Neurobiol. 2022. PMID: 35545730 Review.
-
YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease.Curr Neuropharmacol. 2017;15(6):906-917. doi: 10.2174/1570159X15666170208124324. Curr Neuropharmacol. 2017. PMID: 28183245 Free PMC article. Review.
-
The Function of the Mitochondrial Calcium Uniporter in Neurodegenerative Disorders.Int J Mol Sci. 2017 Feb 10;18(2):248. doi: 10.3390/ijms18020248. Int J Mol Sci. 2017. PMID: 28208618 Free PMC article. Review.
-
Memory-enhancing and brain protein expression-stimulating effects of novel calcium antagonist in Alzheimer's disease transgenic female mice.Pharmacol Res. 2016 Nov;113(Pt B):781-787. doi: 10.1016/j.phrs.2016.06.020. Epub 2016 Jun 21. Pharmacol Res. 2016. PMID: 27345857 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous